Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 729-736

  Shaughnessy, Paul ^a   Islas Ohlmayer, Miguel ^a   Murphy, Julie ^b   Hougham, Maureen ^a   MacPherson, Jill ^a   Winkler, Kurt ^a   Silva, Matthew ^c   Steinberg, Michael ^c   Matous, Jeffrey ^b   Selvey, Sheryl ^c   Maris, Michael ^b   McSweeney, Peter A ^b  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

^b Rocky Mountain Blood and Marrow Transplant Program   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Autologous transplant; Cost analysis; Mobilization; Plerixafor

Indexed keywords

ACICLOVIR; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE PLUS GRANULOCYTE COLONY STIMULATING FACTOR; DEXAMETHASONE; FLUCONAZOLE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR PLUS PLERIXAFOR; LEVOFLOXACIN; LORAZEPAM; MESNA; ONDANSETRON; PLERIXAFOR; PROCHLORPERAZINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CRYOPRESERVATION; DRUG COST; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMOBILIZED CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE COSTS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES;

EID: 79954627405     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.018     Document Type: Article

References (19)

1. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
2. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002, 359:2065-2071.
3. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97.
4. Vose J.M., Ho A.D., Coiffier B., et al. Advance in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009, 50:1412-1421.
5. Weaver C.H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
6. Seggewiss R., Buss E.C., Herrmann D., Goldschmidt H., Ho A.D., Fruehauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF supported chemotherapy. Stem Cells 2003, 21:568-574.
7. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
8. Meldgaard Knudsed L., Jensen L., Gaarsdal E., Nikolaisen K., Johnson H.E. A comparative study of sequential priming and mobilization of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000, 26:717-722.
9. Dazzi C., Cariello A., Rosti G., et al. Is there any difference in PBPC mobilization between cyclophosphosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. Leuk Lymphoma 2000, 3963-40:301-310.
10. Koc O.N., Gerson S.L., Cooper B.W., et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000, 9:1824-1830.
11. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or borezomib-containing regimens. Blood 2009, 114:1729-1735.
12. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
13. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo controlled trial of plerixafor plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
14. DiPersio J.F., Standtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
15. Overview physician fee schedule. United States (US) Department of Health and Human Services Centers for Medicaid Services (HHS/CMS). Available at: Updated May 25th, 2010. Accessed July 2009-March 2010. http://www.cms.gov/PhysicianFeeSched/.
16. Hosing C., Smith V.R., Rhodes B.A., et al. An analysis of the costs associated with peripheral blood hematopoietic progenitor cell mobilization, collection and cryopreservation in patients with lymphomas undergoing autologous stem cell transplantation. Blood 2008, 112. Abstract 2377.
17. Wolf M.S., Fitzner K.A., Powell E.F., et al. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among veterans. J Clin Oncol 2005, 23:8877-8883.
18. Kuderer N.M., Dale D.C., Crawford J., Cosler L., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
19. Pusic I., Fiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.